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ACE-inhibitors have been shown to be effective in
reducing morbidity and mortality in patients with heart
failure due to systolic left ventricular dysfunction, post
myocardial infarction, in patients with hypertension,
and in patients with renal disease associated with di-
abetes mellitus. The heart outcome prevention trial
(HOPE) extended these indications by showing that pa-
tients with vascular disease without a history of heart
failure and those with diabetes mellitus with an addi-
tional risk factor had a significant reduction in death,
nonfatal myocardial infarction, nonfatal stroke, need
for revascularization, and new onset of diabetes mel-
litus [1]. These findings are supported by a wide va-
riety of pre-clinical and clinical studies showing that
ACE-inhibitors reduce oxidative stress, improve ni-
tric oxide availability, endothelial function, activation
of adhesion molecules and cytokines, transport and ox-
idation of LDL cholesterol into macrophages, composi-
tion of the atherosclerotic plaque, as well as preventing
myocardial and perivascular fibrosis and ventricular
hypertrophy [2–5].
Given the accumulating data showing the benefit of
ACE-inhibitors in reducing morbidity and mortality
in patients with coronary artery disease what can we
expect to learn from further trials in this area such as
EUROPA.
EUROPA has much to teach us and its results will
have important implications for future practice. One
important question to be answered by this study is
whether the results of HOPE are specific for ramipril
or are due to a “class effect” of ACE-inhibitors. As
pointed out above there is considerable pre-clinical
and clinical data with a variety of ACE-inhibitors elu-
cidating the mechanisms by which an ACE-inhibitor
might reduce ischemic events. While a specific effect of
ramipril cannot be ruled out it is likely that perindopril
(EUROPA) will also be effective in reducing ischemic
events. While a class effect is likely it is possible that
one or another ACE-inhibitor will be more effective
then another, possibly related to tissue selectivity,
duration of action, and perhaps most importantly
dosing strategy [6]. As more ACE-inhibitors become
available generically, and therefore at relatively low
cost it will be important to have assurance that the
beneficial effects seen in the HOPE trial can be
achieved with other ACE-inhibitors. However, even
if EUROPA confirms the findings of the HOPE trial
clinicians may still face a dilemma in extrapolating the
results of these trials to other ACE-inhibitors, since
the dose of an ACE-inhibitor appears to be critical
in its ability to reduce ischemic events. For example,
the results of the Secure study using ramipril 2.5 mg
or 10 mg examining their effect on the progression
on atherosclerosis, as reflected by carotid intima
media thickness, show that 10 mg daily but not 2.5 mg
daily was effective in reducing the progression of
atherosclerosis [7]. Therefore, it may be hazardous to
extrapolate from the results of EUROPA, even if this
study is positive to other ACE-inhibitors for which we
have no clinical evidence of effectiveness at a given
dose in this indication. It would, I believe, be hazardous
to conclude that two ACE-inhibitors which reduce
blood pressure to an equal degree at given doses will
be equivalent in reducing ischemic events to the same
degree. With these considerations in mind it would
also be hazardous to reject the findings in HOPE even
if EUROPA is negative. Not only are there differences
in the individual ACE-inhibitors, and their dose, but
there are also important differences in patient inclu-
sions in these trials. For example in EUROPA there
is a far broader and possibly lower risk population of
patients with coronary artery disease then in HOPE.
Aside from the question as to class effect what
else can we hope to learn from EUROPA. EUROPA
in my opinion may be particularly important in an-
swering the question as to whether the mechanism
of ACE-inhibitors in reducing nonfatal myocardial
infarction, as seen in HOPE, is related to an effect
of an ACE-inhibitor on the progression of coro-
nary atherosclerosis, plaque rupture, or thrombosis
after plaque rupture. While ACE-inhibitors have
been shown to prevent experimental atherosclerosis
their role in preventing the progression of coronary
atherosclerosis in man is uncertain. The angiographic
sub-study of the QUIET trial of quinapril 20 mg
daily failed to show a significant effect of quinapril
on the progression of coronary atherosclerosis [8].
A retrospective analysis of the QUIET trial has
however suggested that there was a significant effect
of quinapril in preventing coronary atherosclerosis in
patients with an elevated LDL-cholesterol above the
median in that trial, 126 mg dl. An angiographic study of
enalapril (Scat) also failed to demonstrate a significant
effect on the progression of coronary atherosclerosis
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[9]. The secure study showed a significant effect of
ramipril 10 mg daily on the progression of carotid
intima media thickness however the Part 2 study with
ramipril failed to demonstrate a significant effect on
carotid intimal thickness [10]. Differences in method-
ology and dose have been suggested to account for the
discrepant results of ramipril on carotid intima media
thickness. Regardless, at the moment we do not have
an adequate explanation as to why ramipril 10mg re-
duced the incidence of nonfatal infarction and ischemic
events in HOPE. One might postulate that ramipril
was effective in reducing ischemic events not by
preventing the progression of coronary atherosclerosis
but by preventing plaque rupture and or throm-
bosis after plaque rupture. Angiotensin II and the
converting enzyme have been localized in the shoulder
region of the atherosclerotic plaque [11,12] and ACE-
inhibitors shown to decrease metaloproteinase activity
in the plaque and increase collagen content, thereby
improving plaque stability. Angiotensin II by stimulat-
ing NADH/NADPH oxidases in the vascular wall [13]
and oxygen free radical release have been shown to
stimulate various signaling pathways including NFKB
and AP1, which have been associated with a decrease
nitric oxide availability, an increase in tissue factor,
and plasminogin activator inhibitor levels which would
increase thrombosis, and decrease fibrinolysis after
plaque rupture. In addition to its effects on fibrinolysis
plasminogen activator inhibitor may also contribute
to plaque instability. Possibly several processes such
as progression of coronary atherosclerosis, plaque
instability, and thrombosis play an important role in the
effect of ACE-inhibitors in reducing ischemic events.
The sub-studies of EUROPA examining the effect of
perindopril on coronary atherosclerosis by intravas-
cular ultrasound, coagulation factors, and plasminogin
activator inhibitor levels should help to clarify the
relative importance of these mechanisms. While it can
be argued that the exact mechanism by which an ACE-
inhibitor reduces the incidence of nonfatal myocardial
infarction and ischemic events is less important then
the fact that ischemic events are reduced an under-
standing of the mechanism by which ischemic events
are reduced will be useful in designing future strate-
gies. For example, should an ACE-inhibitor be shown
to be effective in preventing new coronary artery lesion
formation, such as has been demonstrated with a statin,
agents that further improve plaque stability and/or
agents that decrease thrombosis after plaque rupture
may be important. Conversely, if ACE-inhibitors pre-
vent plaque rupture without effecting the progression
of atherosclerosis agents such as a statin which have
been clearly shown to prevent new coronary lesion
formation and the progression of atherosclerosis may
be important adjunctive strategies.
Clearly, the results of EUROPA will have impor-
tant implications for future practice in regard to the
question of class effectiveness, extrapolation of the re-
sults of HOPE to a broader group of patients with
coronary artery disease and possibly patients with
lower risk profiles, and an understanding of the mecha-
nisms by which the beneficial effects of ACE-inhibitors
are achieved. EUROPA is however only a waypoint in
our understanding of the role of the renin angiotensin
system in ischemic heart disease. Other trials of ACE-
inhibitors such as PEACE with trandolapril and new
trials comparing ACE-inhibitors to angiotensin recep-
tor blocking agents and their combination are under-
way as well as the new trials exploring the effects of
ACE-inhibitors to prevent diabetes mellitus. There is
also emerging data that aldosterone receptor block-
ing agents may have an important effect in reducing
ischemic events in view of their effectiveness in restor-
ing endothelial function and reducing oxygen free
radical formation in experimental hyperlipidemic rab-
bits. Further studies exploring the synergestic or
additive effects of ACE-inhibitors and statins, ACE-
inhibitors, and antithrombotic or anti-platelet strate-
gies, as well as anti-inflammatory strategies are clearly
needed. Although the epidemic of ischemic heart dis-
ease continues the demonstration of the effectiveness
of statins, ACE-inhibitors, anti-thrombotic, and anti-
platelet strategies make me hopeful although that the
epidemic is not eradicated it is being contained. Only
through further well-designed pre-clinical studies and
large-scale randomized trials such as EUROPA can we
hope to claim victory.
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